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Background. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been introduced as a novel repeatable treatment
for peritoneal carcinomatosis. The available evidence from the pioneer center suggests good tolerance and high response
rates, but independent conﬁrmation is needed. A single-center cohort was analyzed one year after implementation for feasibility
and safety. Methods. PIPAC was started in January 2015, and every patient was entered into a prospective database. This
retrospective analysis included all consecutive patients operated until April 2016 with emphasis on surgical feasibility and early
postoperative outcomes. Results. Forty-two patients (M : F = 8 : 34, median age 66 (59–73) years) with 91 PIPAC procedures in
total (4×: 1, 3×: 17, 2×: 12, and 1×: 12) were analyzed. Abdominal accessibility rate was 95% (42/44); laparoscopic access was
not feasible in 2 patients with previous HIPEC. Median initial peritoneal carcinomatosis index (PCI) was 10 (IQR 5–17).
Median operation time was 94min (89–108) with no learning curve observed. One PIPAC application was postponed due to
intraoperative intestinal lesion. Overall morbidity was 9% with 7 minor complications (Clavien I-II) and one PIPAC-unrelated
postoperative mortality. Median postoperative hospital stay was 3 days (2-3). Conclusion. Repetitive PIPAC is feasible in most
patients with refractory carcinomatosis of various origins. Intraoperative complications and postoperative morbidity rates were
low. This encourages prospective studies assessing oncological eﬃcacy.
1. Introduction
Peritoneal carcinomatosis (PC) remains a condition with
limited treatment options and dismal prognosis [1–3].
Outcome appears to be worse for PC compared to other
stage IV situations, and response rates to systemic chemo-
therapy are modest at best, mainly due to limited tissue
concentrations [4, 5]. Furthermore, side eﬀects are com-
mon, and the use of palliative chemotherapy has therefore
been questioned recently [6–8]. Hyperthermic intraperito-
neal chemotherapy has been suggested in conjunction with
cytoreductive surgery as an alternative in selected patients
with encouraging results. However, most patients with PC
are not eligible for this major procedure associated with
important morbi-mortality [9, 10]. Furthermore, tissue con-
centrations after HIPEC remain low due to unequal distribu-
tion and low penetration [11].
Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
has been introduced as a novel treatment for peritoneal
carcinomatosis [12, 13]. Pressure application allows for equal
distribution and deeper penetration resulting in higher tissue
concentrations despite lower doses (low systemic uptake)
[14–16]. Minimally invasive access without cytoreduction
decreases morbidity and allows for repetitive application.
PIPAC is a very new technique, and ﬁrst human applica-
tion took place in November 2011 only. So far, all clinical
reports but one came from the pioneer center in Herne,
Germany [17–20].
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The aim of this study was to analyze and report a con-
secutive cohort of PIPAC patients in our tertiary center
with regard to feasibility and safety of the procedure.
2. Methods
The PIPAC program was started at the Department of
Visceral Surgery of the University Hospital of Lausanne,
Switzerland (CHUV), in January 2015, and was endorsed
by the medical direction. Eligibility criteria for PIPAC
treatment were persistent or progressive isolated peritoneal
disease under or after at least one line of systemic treatment.
Cytoreductive surgery and HIPEC as potentially curative
treatment option was always the preferred choice in the
absence of contraindications. Exceptionally, patients with
predominating symptomatic PC and very limited disease
elsewhere were considered. All patients were seen in the out-
patient setting by a surgeon together with an oncologist to
discuss all available treatment options. All indications were
conﬁrmed at the multidisciplinary tumor board. Patients
received detailed oral and written information about the
nature and risk of this novel procedure, and all patients
provided written consent prior to surgery. All patients were
treated in a palliative setting since long-term outcomes after
PIPAC treatment is not yet available. This important point
was explicitly stated in the preoperative information and
consenting session. According to Swiss legislation and our
institutional directive, all patients were further asked for their
consent for the utilization of their clinical data in anonymous
form (general consent).
This retrospective analysis included all consecutive
patients scheduled for PIPAC from the beginning of the
program (January 2015) until April 2016. Excluded were only
those patients refusing to sign the general consent form. The
study was approved by the Institutional Review Board (num-
ber 2016-00274), conducted and reported in compliance with
the STROBE criteria (http://strobe-statement.org/), and reg-
istered online (http://www.researchregistry.com; UIN: 1577).
2.1. PIPAC Procedure (Figure 1 [21]). Surgical technique and
safety considerations have been described in detail by the
Herne group, and our institutional protocol adhered strictly
to these empirical standards [13, 16, 22]. Brieﬂy, pneumo-
peritoneum was established by open placement of one
10mm and one 5mm balloon trocar, additional 5mm tro-
cars only if needed for technical diﬃculty. The peritoneal
carcinomatosis index (PCI) was documented, and repre-
sentative peritoneal nodules were biopsied. Intraperitoneal
chemotherapy was applied by the use of a pressure injector
(Accutron HP-D, Medtron®, Saarbrücken, Germany) and
a speciﬁc nebulizer (MicroPump®, CapnoPen®, Reger,
Villingendorf, Germany) at 37°C for 30min and under
standard laparoscopic pressure of 12mmHg [23]. PIPAC
was administered repetitively (3× at least) at an interval of
about 6 weeks. In line with current protocols, patients with
PC of colorectal origin received oxaliplatin (92mg/m2), while
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Figure 1: Pressurized intraperitoneal aerosol chemotherapy (PIPAC). The abdominal cavity is accessed with 2 balloon trocars allowing
hermetic seal. Liquid chemotherapy is dispersed as aerosol by use of a standard injector and a speciﬁc nebulizer. Reprinted from Rev Med
Suisse [21] with permission from Médicine et Hygiène.
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a combination of cisplatin (7.5mg/m2) and doxorubicin
(1.5mg/m2) was applied for the other malignancies [17–19].
2.2. Data Management and Outcome Measures. Demo-
graphic information and surgical details were prospectively
entered for all patients in a computerized coded database
designed speciﬁcally for quality control of the PIPAC cohort.
Demographic data included age, gender, comorbidities, and
nutritional status. American Association of Anesthesiologists
(ASA) physical status and Eastern Cooperative Oncology
Group (ECOG) performance status were documented as
validated tools to describe general condition [24]. Nutritional
risk was assessed by the use of the Nutritional Risk Score
(NRS 2002) [25].
Surgical information contained operation time, intra-
operative complications, need for concomitant adhesioly-
sis, accessibility of the abdomen, and number of trocars.
Extent of peritoneal disease was documented by the use
of the peritoneal cancer index (PCI) [26], and volume of
ascites was measured. Surgical stress was assessed using
the E-PASS (Estimation of Physiologic Ability and Surgical
Stress) score [27].
Postoperative morbidity was assessed until 30 days after
surgery by use of the Clavien classiﬁcation, and length of
postoperative hospital stay was measured including readmis-
sions. Outpatient appointments were scheduled for all
patients at 30 days after each procedure for clinical follow-
up and quality control. Moreover, each patient received an
emergency phone number and was advised to establish
contact if a problem arises.
2.3. Predeﬁned Clinical Questions. Several comparisons and
statistical correlations were deﬁned a priori. Univariate
analysis was compared between patients with only one
PIPAC versus patients with repeated applications. This
was done to deﬁne conditions rendering repetitive admin-
istration diﬃcult.
Gynecological malignancies diﬀer from digestive cancers
in many ways including previous surgical and systemic treat-
ments and distribution patterns of peritoneal carcinomatosis.
As this has a potential impact on surgical diﬃculty and
approach, surgical aspects between gynecological and diges-
tive patients were compared.
Lastly, increasing peritoneal tumor loadmight complicate
surgery and reﬂect more advanced disease with consecutive
longer hospital stay. In order to test these hypotheses, we
correlated PCI to operation time and postoperative hospital
stay, respectively.
2.4. Statistical Analysis. Continuous variables were presented
as mean with standard deviation (SD) or median value with
range or interquartile range (IQR) as appropriate depending
on the normality of the distribution and compared using
Student’s t-test and Mann-Whitney U test. Categorical
variables were given as frequencies with percentages and
compared with chi-square test. Spearman’s test was used
to measure correlations between continuous variables. A
p value of <0.05 was considered to be statistically signiﬁ-
cant in all tests. Data analyses were generated using SPSS
v20 statistical software (Chicago, IL, USA); graphics were
developed using GraphPad Prism 7 (GraphPad Software
Inc., La Jolla, CA, USA).
3. Results
In the study period, 44 patients were scheduled for PIPAC. In
2 patients, no laparoscopic access could be established due to
dense adhesions. All remaining patients had signed the
general consent form, and no patient was excluded. Final
analysis included therefore 42 patients (M : F= 8 : 34, median
age 66 (IQR 59–73) years). Overall failure rate (number of
nonaccess + aborted procedures/total number of attempted
procedures) was 4/95 (4%) (Figure 2). Twenty-one patients
(50%) had carcinomatosis of ovarian origin, 14 and 3 from
colorectal and gastric cancer, respectively (remainder: 1 small
bowel, 1 pseudomyxoma, and 1mesothelioma). Demographic
information is provided in Table 1.
Overall, 91 PIPAC procedures were performed; 18
patients had 3 or more PIPAC procedures, 12 patients had 2
operations, and 12 patients one procedure so far. Reasons
for no 2nd PIPAC were progression of systemic disease in 5
patients, patient refusal in 3, absent peritoneal disease during
ﬁrst PIPAC in one, and secondary nonaccess during the 2nd
PIPAC in one patient. The 2 remaining patients were awaiting
their scheduled 2nd intervention. Patients with higher ASA
score, lower BMI, underlying malnutrition, and colorectal
origin were less likely to undergo repetitive PIPAC (Table 1).
3.1. Surgical Details (Table 2). In 80 out of the 91 procedures
(88%), one 5mm and one 10mm trocar were used; 3 trocars
were needed in 11 surgeries. Median overall time for all
procedures was 94min (IQR 89–108) showing little variation
over time. PIPAC procedures for gynecological peritoneal
metastases were signiﬁcantly shorter as compared with
procedures for digestive PC. Surgical stress as measured by
the E-PASS was a median of −0.20 (−0.32–−0.11). Median
PCI was 10 (5–17), and adhesiolysis was necessary in 16% of
cases before applying PIPAC. There was one intraoperative
complication: a small bowel lesion occurred during open
trocar placement. The enterotomy was recognized and
repaired immediately. PIPAC was postponed and successfully
performed six weeks later.
In patients with digestive origin, median PCI was sig-
niﬁcantly higher and operation time signiﬁcantly longer.
3.2. Postoperative Outcomes. Eight complications occurred
after 91 procedures, giving an overall morbidity rate of
8.8%. Seven minor complications were 3 urinary retentions
with a need for 24 h catheterization, one ileus treated with
nasogastric decompression, one minor scar bleeding, one
constipation requiring enema, and one neutropenia with
spontaneous resolution. One patient developed cardiogenic
shock and arrhythmia 4 days after the 3rd PIPAC procedure
with fatal outcome. Autopsy did not ﬁnd any intra-
abdominal complication, and no causative link could be
established between PIPAC treatment and death.
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Median hospital stay was 3 (IQR 2-3) days with 9 and 35
patients, respectively, who left the hospital on the 1st and 2nd
postoperative days.
3.3. Correlation of Tumor Load, Operation Time, and
Hospital Stay. Higher PCI was signiﬁcantly associated
with shorter OR time (ρ = − 0 291, p = 0 005), while no
statistical correlation was found between PCI and hospital
stay (ρ = 0 193, p = 0 067) (Figures 3(a) and 3(b)).
4. Discussion
In the present study, repeated PIPAC was feasible in most
patients with peritoneal carcinomatosis. Postprocedure mor-
bidity was low and hospital stay short.
Feasibility of PIPAC includes abdominal access by
laparoscopy and repeated application. Minimally invasive
surgery in patients with multiple prior surgeries is challen-
ging and associated with higher conversion rates [28, 29].
For PIPAC in particular, the literature is very scarce.
Reported primary nonaccess rates vary from 0 to 17%;
after at least one PIPAC, secondary nonaccess rate was
reported to be 0–35% [17–20]. In our series, we observed
primary and secondary nonaccess rates of 4.5% and 2.4%,
respectively; of note, both patients with primary nonaccess
had prior HIPEC treatment. Repeatability is more complex
and depends not only on technical problems but mostly on
disease progression and preferences of patients and their care
providers. Altogether, 10 out of 42 patients (23.8%) could not
beneﬁt from the 2nd PIPAC mostly due to the development
of metastases other than peritoneal (n = 5) or for patient’s
wish to discontinue treatments (n = 3). Our ﬁndings are in
line with the ﬁndings from the Herne group reporting
repeated application in 64–82% of their patients [17–19].
Intraoperative complications appear to be exceedingly
rare, but the risk for small bowel lesions is present in patients
with adhesions as also reported by others [18]. Besides the
mortality described in this paper, 2 fatal outcomes after
PIPAC treatment have been reported in the literature [18].
Mortality was attributed to progressing small bowel disease
causing obstruction in one patient and poor general condi-
tion with consecutive ascitic decompensation and renal
failure in the other patient. Tempfer et al. suggested there-
fore that impeding small bowel obstruction and refractory
ascites should be considered as contraindications to PIPAC
treatment. Therefore, proper patient selection is important
and challenging as patients tend to accept risks in view of
lacking treatment alternatives in most cases. No CTCAE
(Common Terminology Criteria for Adverse Events) grade
4 events were reported after PIPAC, while incidence of
grade 3 events varied between 23 and 35% [17–20]. Apply-
ing the Clavien classiﬁcation for postoperative complications,
we observed an overall morbidity of 9% in our series. Postop-
erative abdominal pain, which was present in the Herne
experience in up to 100% [17], required rarely other analge-
sics than those routinely used after other laparoscopic proce-
dures like cholecystectomy. The median hospital stay was 3
days, similar as reported by an Italian group [20]. Reporting
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Figure 2: Flow of patients treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).
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a considerable number of patients leaving hospital already
1-2 days after surgery, even outpatient surgery might be
considered in the future for well-selected patients in good
general condition. However, it must be underlined that the
usual PIPAC patient is frail and in reduced general condi-
tion due to the disease and previous treatments. Caution is
Table 1: Baseline demographics of patients treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).
All patients (n = 42) 1 PIPAC (n = 12) 2 or >3 PIPAC (n = 30) p value
Demographics
Median age (years) 66 (59–73) 62 (52–88) 67 (61–63) 0.185
Age≥ 70 years 16 (38%) 4 (33%) 12 (40%) 0.687
Gender (male) 8 (19%) 4 (33%) 4 (13%) 0.135
Median BMI (kg/m2) 22.5 (20–25) 19 (19–23) 22.7 (21.3–26) 0.018
BMI < 18.5 kg/m2 2 (5%) 1 1 0.491
Comorbidities
ASA (I-II) 28 (66%) 5 (42%) 23 (77%) 0.029
ECOG (0-1) 36 (86%) 9 (75%) 27 (90%) 0.209
Diabetes 1 (2%) 1 0 0.109
Malnutrition 14 (33%) 7 (58%) 7 (23%) 0.029
NRS < 3 29 (69%) 6 (50%) 23 (77%) 0.091
Previous laparotomy 1 (0–4) 1 (0–3) 1 (0–4) 0.040
≥2 15 (36%) 2 (16%) 13 (43%) 0.103
Disease
Origin 0.007
Colorectal 15 (33%) 8 (66%) 6 (20%)
Gastric 3 (7%) 0 3 (10%)
Gynecological 21 (50%) 2 (17%) 19 (63%)
Other 3 1 2
Prior chemotherapy 0.229
No chemo 2 1 1
1 line 9 (21%) 5 (42%) 4 (13%)
2 lines 13 (31%) 2 (17%) 11 (36%)
3 lines 9 (21%) 1 8 (26%)
More than 3 9 (21%) 3 (25%) 6 (20%)
Prior HIPEC 4 (10%) 2 (17%) 2 (7%) 0.318
Diagnosis—1st PIPAC (mo) 16 (1–104) 18 (1–73) 16 (1–104) 0.928
Median (range) for previous laparotomy and diagnosis—1st PIPAC, otherwise median (IQR) or number (%) as appropriate. Statistical signiﬁcance (p < 0 05) is
highlighted in italics.
BMI: body mass index; ASA: American Association of Anesthesiologists physical status classiﬁcation system; ECOG: Eastern Cooperative Oncology Group
performance status; HIPEC: hyperthermic intraperitoneal chemotherapy.
Table 2: Surgical details of pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Overall (n = 91) GYN (n = 51) Digestive (n = 40) p value
Surgical feasibility
Number of trocars 2 (2-3) 2 (2-3) 2 (2-3) 0.668
Operation time 94 (89–108) 91 (87–97) 100 (92–117) 0.002
Intra-OP ﬁndings
PCI 10 (5–17) 9 (4–14) 15 (7–19) 0.002
Ascites (mL) 50 (0–4000) 0 (0–300) 50 (0–4000) 0.982
Adhesiolysis 15 (16%) 9 (18%) 6 (15%) 0.735
Median E-PASS −0.20 (−0.32–−0.11) −0.20 (−0.31–−0.10) −0.20 (−0.31–−0.09) 0.733
Median (range) for number of trocars and ascites andmedian (IQR) for operation time, PCI, andE-PASS. Statistical signiﬁcance (p < 0 05) is highlighted in italics.
PCI: peritoneal cancer index; E-PASS: Modiﬁed Estimation of Physiologic Ability and Surgical Stress.
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advocated especially for malnourished patients presenting
with ascites as postoperative ﬂuid shifts can be important
entailing consecutive electrolyte disturbances and renal fail-
ure. But even those negatively selected patients required rarely
more than 3 days after surgery before being ﬁt for discharge.
Extent of peritoneal disease (as measured by the PCI)
was in the present experience not associated with increased
operation time, rather the contrary. Most patients with
advanced peritoneal disease had considerable amounts of
ascites facilitating abdominal access and also choice of appro-
priate location for biopsies. To our knowledge, impact of PCI
on operation time has not been investigated by other groups.
The present study did not observe any signiﬁcant correlation
between PCI and postoperative stay; these ﬁndings conﬁrm
that PIPAC treatment is feasible and safe within short hospi-
tal stay even for patients with very advanced disease [20].
Selection and reporting bias are important limitations
of retrospective studies. The present analysis included all
consecutive patients without any exclusion. All reported
endpoints were deﬁned a priori and documented online
in a prospectively maintained database designed for quality
control. The study sample however was modest and hetero-
geneous. Heterogeneity concerns especially prior surgical
and systemic chemotherapy treatments which is a methodo-
logical problem in studies on peritoneal carcinomatosis in
general. Comparisons with other cohorts treated intraperito-
neally or systemically are hence problematic. Therefore, fur-
ther data is certainly needed to conﬁrm the present ﬁndings
even if they are in line with data published so far.
In conclusion, the present study suggests that repeti-
tive PIPAC is feasible in most patients with refractory
carcinomatosis of various origins. Intraoperative events
and postoperative complications are low. These ﬁndings
encourage designing prospective studies assessing oncolog-
ical eﬃcacy.
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